$176.02 Million in Sales Expected for Cambrex Co. (CBM) This Quarter

Equities research analysts expect Cambrex Co. (NYSE:CBM) to report sales of $176.02 million for the current quarter, Zacks reports. Three analysts have made estimates for Cambrex’s earnings. The lowest sales estimate is $158.82 million and the highest is $210.17 million. Cambrex reported sales of $182.28 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 3.4%. The business is expected to issue its next earnings results on Thursday, February 14th.

According to Zacks, analysts expect that Cambrex will report full-year sales of $556.70 million for the current year, with estimates ranging from $556.58 million to $556.82 million. For the next fiscal year, analysts forecast that the company will report sales of $691.12 million, with estimates ranging from $639.25 million to $723.61 million. Zacks’ sales averages are an average based on a survey of analysts that follow Cambrex.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.10). Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The business had revenue of $104.62 million for the quarter, compared to the consensus estimate of $122.04 million. During the same period in the prior year, the company earned $0.55 EPS. Cambrex’s quarterly revenue was down 7.1% on a year-over-year basis.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $51.00 price objective for the company in a research report on Wednesday. ValuEngine raised shares of Cambrex from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 5th. TheStreet downgraded shares of Cambrex from a “b” rating to a “c+” rating in a research report on Monday, December 3rd. Robert W. Baird assumed coverage on shares of Cambrex in a research report on Thursday, November 15th. They set an “outperform” rating for the company. Finally, First Analysis raised shares of Cambrex from an “outperform” rating to a “strong-buy” rating and lowered their price objective for the company from $73.00 to $63.00 in a research report on Friday, November 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $63.17.

In other Cambrex news, CEO Steven M. Klosk sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 23rd. The shares were sold at an average price of $54.76, for a total value of $1,095,200.00. Following the completion of the transaction, the chief executive officer now owns 103,328 shares in the company, valued at approximately $5,658,241.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.42% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in shares of Cambrex by 8.7% in the second quarter. BlackRock Inc. now owns 4,624,250 shares of the biotechnology company’s stock valued at $241,849,000 after acquiring an additional 370,806 shares in the last quarter. Franklin Resources Inc. lifted its stake in Cambrex by 117.6% during the third quarter. Franklin Resources Inc. now owns 503,600 shares of the biotechnology company’s stock valued at $34,446,000 after purchasing an additional 272,117 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Cambrex by 104.3% during the third quarter. Acadian Asset Management LLC now owns 483,763 shares of the biotechnology company’s stock valued at $33,090,000 after purchasing an additional 247,016 shares during the last quarter. Copper Rock Capital Partners LLC lifted its stake in Cambrex by 161.4% during the fourth quarter. Copper Rock Capital Partners LLC now owns 391,490 shares of the biotechnology company’s stock valued at $14,771,000 after purchasing an additional 241,749 shares during the last quarter. Finally, William Blair Investment Management LLC lifted its stake in Cambrex by 9.9% during the third quarter. William Blair Investment Management LLC now owns 2,530,397 shares of the biotechnology company’s stock valued at $173,079,000 after purchasing an additional 228,059 shares during the last quarter.

Shares of NYSE:CBM traded down $0.16 during trading on Friday, reaching $46.78. 315,500 shares of the company’s stock traded hands, compared to its average volume of 448,475. The company has a quick ratio of 3.41, a current ratio of 4.54 and a debt-to-equity ratio of 0.49. Cambrex has a 12 month low of $35.98 and a 12 month high of $69.43. The company has a market cap of $1.53 billion, a PE ratio of 14.77, a P/E/G ratio of 1.54 and a beta of 2.40.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

See Also: What is a put option?

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply